GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Read-Gene SA (WAR:RDG) » Definitions » Loans Receivable

Read-Gene (WAR:RDG) Loans Receivable : zł0.00 Mil (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Read-Gene Loans Receivable?

Read-Gene's Loans Receivable for the quarter that ended in Sep. 2024 was zł0.00 Mil.


Read-Gene Loans Receivable Historical Data

The historical data trend for Read-Gene's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Read-Gene Loans Receivable Chart

Read-Gene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Read-Gene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Read-Gene Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Read-Gene Loans Receivable Related Terms

Thank you for viewing the detailed overview of Read-Gene's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Read-Gene Business Description

Traded in Other Exchanges
N/A
Address
Ulica Alabastrowa 8, Grzepnica, Dobra, POL, 72-003
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.

Read-Gene Headlines

No Headlines